Based on the reported case, we highly recommend performing genetic testing in case of thrombocytopenia and absent or decreased megakaryocytes, as CAMT2 is mild and can respond to THPO receptor agonists while avoiding invasive, ineffective bone marrow transplantation for these THPO gene mutations. This evidence concerns the gene THPO and Thrombocytopenia.